RxDoctor Payments Data

Kristen O Dwyer, MD

Hematology · Rochester, NYNPI 1417286501

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Astellas Pharma US Inc accounts for 75.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology clinicians in NY, where the typical reported total is $619.

$99in general payments, 2019–2025

Across 2 payments — averaging $49.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$75
  • Gilead$25
$1,945,839in research payments, 2019–2025

Across 141 payments — averaging $13,800 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1.8M
  • Astellas Pharma Global Development$56K
  • Autolus Inc$22K
  • Servier Bioinnovation$22K
  • Amgen$313

What the payments were for

  • Food & beverage$99100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc1$75
Gilead1$25

How this compares

$99 in reported general payments places this provider in the 25th percentile of 157 hematology providers in New York.

See all hematology providers in New York

Medicare billing

Part B allowed, 2024
$34,431
Medicare patients
90
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →